Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma PatientsRecruiting
NCT06284590Phase 2Updated Sep 2, 2026
Sponsor: Philogen S.p.A.
Melanoma Stage III · Melanoma Stage IV
United States, Germany, Italy
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China ExtensionCompleted
NCT04934722Phase 3Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Hormone-Sensitive Prostate Cancer
China
A Study of V132 in Healthy Older Participants (V132-001)Recruiting
NCT07712575Phase 1Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)Completed
NCT06442436Phase 1Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Hepatic Impairment (HI)
United States
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)Not Yet Recruiting
NCT07743164Phase 3Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
SW-682 in Advanced Solid TumorsRecruiting
NCT06251310Phase 1Updated Sep 2, 2026
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Advanced Solid Tumor · Mesothelioma, Malignant
United States
Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)Completed
NCT05289856Phase 2Updated Sep 1, 2026
Sponsor: Johannes Gutenberg University Mainz
Cancer
Germany
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)Active Not Recruiting
NCT03998254Phase 3Updated Sep 1, 2026
Sponsor: Merck Sharp & Dohme LLC
Papillomavirus Infections
China
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)Completed
NCT04996797Phase 2Updated Sep 1, 2026
Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Ulcerative Colitis
United States, Australia, Belgium, Canada, Czechia +7 more
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)Completed
NCT05508867Phase 2Updated Sep 1, 2026
Sponsor: Merck Sharp & Dohme LLC
Hodgkin Lymphoma
United States, Argentina, Australia, Belgium, Brazil +15 more
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid TumorsRecruiting
NCT06983743Phase 1Updated Sep 1, 2026
Sponsor: Erasca, Inc.
Metastatic Solid Tumors
United States
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruiting
NCT02693535Phase 2Updated Sep 1, 2026
Sponsor: American Society of Clinical Oncology
Lymphoma, Non-Hodgkin · Multiple Myeloma · Advanced Solid Tumors
United States, Puerto Rico
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)Not Yet Recruiting
NCT07791732Phase 3Updated Sep 1, 2026
Sponsor: Daiichi Sankyo
Fallopian Tube Cancer · Primary Peritoneal Cancer · High-Grade Serous Ovarian Cancer · Endometrioid Epithelial Ovarian
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)Completed
NCT04305041Phase 1, Phase 2Updated Sep 1, 2026
Sponsor: Merck Sharp & Dohme LLC
Melanoma
United States, Australia, France, Israel, Italy +2 more
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung CancerActive Not Recruiting
NCT04619004Phase 2Updated Sep 1, 2026
Sponsor: Daiichi Sankyo
Non-Small Cell Lung Cancer Metastatic · Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
United States, Australia, Austria, Belgium, Bulgaria +11 more
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)Active Not Recruiting
NCT07216482Phase 3Updated Sep 1, 2026
Sponsor: Merck Sharp & Dohme LLC
Hyperlipidemia
United States, Argentina, Australia, Brazil, Canada +6 more
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)Recruiting
NCT06788912Phase 2Updated Sep 1, 2026
Sponsor: Merck Sharp & Dohme LLC
Lung Neoplasm Malignant
United States, Chile, Greece, Hungary, Italy +4 more
ESCUDDO Long Term Follow UpEnrolling By Invitation
NCT07706673Phase 4Updated Sep 1, 2026
Sponsor: National Cancer Institute (NCI)
Human Papillomavirus Infection · Human Papillomavirus-Related Malignant Neoplasm
Costa Rica
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric AdenocarcinomaCompleted
NCT04209686Phase 2Updated Sep 1, 2026
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Gastric Adenocarcinoma
United States
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)Recruiting
NCT07232602Phase 1, Phase 2Updated Sep 1, 2026
Sponsor: Merck Sharp & Dohme LLC
Bladder Cancer
United States, Chile, France, Israel, Netherlands +3 more
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Active Not Recruiting
NCT05327530Phase 2Updated Sep 1, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Locally Advanced or Metastatic Urothelial Carcinoma
United States, Australia, Belgium, Canada, France +7 more
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive Not Recruiting
NCT03547973Phase 2Updated Sep 1, 2026
Sponsor: Gilead Sciences
Metastatic Urothelial Cancer
United States, France, Germany, Greece, Italy +4 more
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)Not Yet Recruiting
NCT07776691Phase 3Updated Aug 31, 2026
Sponsor: Merck Sharp & Dohme LLC
Ovarian Cancer · Ovarian Neoplasms · Peritoneal Cancer · Fallopian Tube Cancer
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent GlioblastomaCompleted
NCT04201873Phase 1Updated Aug 31, 2026
Sponsor: Jonsson Comprehensive Cancer Center
Recurrent Glioblastoma
United States
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)Terminated
NCT02625961Phase 2Updated Aug 31, 2026
Sponsor: Merck Sharp & Dohme LLC
Bladder Cancer

Previous page Next page